Bone Marrow CD34+/lin− Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subj

We observed that certain transcriptome features present at diagnosis persisted after 12 months of nilotinib treatment, compared to CTRLs. This suggests that nilotinib may exert selective pressure, potentially supporting the survival and self-renewal of LSCs. Future insights into these pathways could help identify therapeutic targets to improve outcomes in CML.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2025-03-18
DOI
https://doi.org/10.3390/cancers17061022
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bone Marrow CD34+/lin− Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subj

Mauro Turrini, Ester Pungolino, Michela Anghilieri, Alessandro Beghini et al.
Cancers
Chronic Myeloid Leukemia Treatments
article

Bone Marrow CD34+/lin− Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subj

Mauro Turrini, Ester Pungolino, Michela Anghilieri, Alessandro Beghini, Alessandra Iurlo, Salvatore Artale, Maria Cristina Carraro, Cristina Bucelli, Roberto Cairoli, Chiara Elena, Simona Malato, Maria Luisa Latargia, Pierangelo Spedini, Alessandra Perego, Alessandra Trojani, Francesco Spina, Barbara Di Camillo, Luca Emanuele Bossi, Cassandra Palumbo, Lorenza Borin, Mariella D’Adda
article en

Abstract

We observed that certain transcriptome features present at diagnosis persisted after 12 months of nilotinib treatment, compared to CTRLs. This suggests that nilotinib may exert selective pressure, potentially supporting the survival and self-renewal of LSCs. Future insights into these pathways could help identify therapeutic targets to improve outcomes in CML.

CancersVol. 17(6)
University of Padua (IT), University of Milan (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Azienda Ospedaliera San Gerardo (IT), Ospedale di Circolo di Busto Arsizio (IT), Policlinico San Matteo Fondazione (IT), Azienda Ospedaliera di Desio e Vimercate (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), ASST Fatebenefratelli Sacco (IT), Ospedale Valduce (IT), Istituti Ospitalieri di Cremona (IT), Azienda Socio Sanitaria Territoriale di Cremona
Good health and well-being
Openalex Percentile: Top 93%
Chronic Myeloid Leukemia Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.